secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001140361-24-013726
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers Squibb completes $330/share acquisition of Karuna Therapeutics, adds schizophrenia drug KarXT
--------------------------------------------------------------------------------

- Each Karuna share converted into $330 cash; deal closed March 18, 2024.
- Lead asset KarXT (xanomeline-trospium) has PDUFA date Sept 26, 2024 for schizophrenia.
- Transaction expected to be dilutive ~$0.30 to non-GAAP EPS in 2024 from financing costs.
- One-time ~$12B Acquired IPR&D charge impacts Q1 2024 GAAP/non-GAAP EPS by ~$5.93.
- BMS to update financial outlook when reporting Q1 2024 results on April 25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000114036124013726/0001140361-24-013726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000114036124013726/ef20024275_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-013726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer